Boehringer Ingelheim in Oncology
Cancer takes away loved ones, time and untapped potential. At Boehringer Ingelheim we are providing new hope for patients by taking cancer on. We are collaborating with the oncology community to deliver scientific breakthroughs to transform the lives of patients. Our primary focus is in lung and gastrointestinal cancers, with the goal of delivering breakthrough, first-in-class treatments that can help win the fight against cancer. Our commitment to innovation has resulted in pioneering treatments for lung cancer and we are advancing a unique pipeline of cancer cell directed agents, immune oncology therapies and intelligent combination approaches to help combat many cancers.
To find out more about our ongoing collaborations, approved and investigational compounds, oncology meetings and congresses, symposia and other activities sponsored by Boehringer Ingelheim www.inoncology.com
Boehringer Ingelheim has produced slide kits that discuss the epidemiology, disease classification and pathology of non-small-cell lung carcinoma (NSCLC), head and neck squamous-cell carcinoma (HNSCC) and (squamous non-small-cell lung carcinoma) SqNSCLC.
Follow Boehringer Ingelheim on social media!